Nanog signaling in cancer promotes stem-like phenotype and immune evasion

Journal of Clinical Investigation

Volumn 122, Issue 11, 2012, Pages 4077-4093

  Noh, Kyung Hee ^a   Kim, Bo Wook ^b   Song, Kwon Ho ^a   Cho, Hanbyoul ^c   Lee, Young Ho ^a   Kim, Jin Hee ^a   Chung, Joon Yong ^b   Kim, Jae Hoon ^c   Hewitt, Stephen M ^b   Seong, Seung Yong ^d   Mao, Chih Ping ^e   Wu, T C ^e   Kim, Tae Woo ^a  

^a Korea University College of Medicine   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B; TRANSCRIPTION FACTOR NANOG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER STEM CELL; COLON CANCER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR ESCAPE;

ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; HOMEODOMAIN PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR ESCAPE;

EID: 84868618042     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64057     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. Ca-a Cancer Journal for Clinicians. 2012;62(1):10-29.
2. Wilczynski JR, Duechler M. How do tumors actively escape from host immunosurveillance? Arch Immunol Ther Exp (Warsz). 2010;58(6):435-448.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
5. Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci. 2009; 1176:154-169.
6. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120(1):41-50.
7. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275-284. (Pubitemid 40488633)
8. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011;9(1):50-63.
9. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007; 58:267-284. (Pubitemid 46706514)
10. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27(12):1749-1758. (Pubitemid 351380265)
11. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755-768.
12. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8(10):806-823.
13. Singec I, et al. Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology. Nat Methods. 2006;3(10):801-806. (Pubitemid 44445827)
14. Noh KH, et al. Cancer vaccination drives Nano-g- dependent evolution of tumor cells towards an immune-resistant and stem-like phenotype. Cancer Res. 2012;72(7):1717-1727.
15. Oh JH, et al. Identification of a putative transactivation domain in human Nanog. Exp Mol Med. 2005;37(3):250-254.
16. Do HJ, et al. Two potent transactivation domains in the C-terminal region of human NANOG mediate transcriptional activation in human embryonic carcinoma cells. J Cell Biochem. 2009;106(6):1079-1089.
17. Lee MY, Lee SH, Park JH, Han HJ. Interaction of galectin-1 with caveolae induces mouse embryonic stem cell proliferation through the Src, ERas, Akt and mTOR signaling pathways. Cell Mol Life Sci. 2009;66(8):1467-1478.
18. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195-203.
19. Han HD, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010;16(15):3910-3922.
20. Han HD, et al. A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm. 2008;350(1-2):27-34. (Pubitemid 351146677)
21. Lu C, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010;18(2):185-197.
22. Zielske SP, Spalding AC, Wicha MS, Lawrence TS. Ablation of breast cancer stem cells with radiation. Transl Oncol. 2011;4(4):227-233.
23. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127-1134.
24. Ginestier C, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010;120(2):485-497.
25. Wu A, et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev. 2008;17(1):173-184. (Pubitemid 351271617)
26. Chiou SH, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010;70(24):10433- 10444.
27. Brandner S. Nanog, Gli, and p53: a new network of stemness in development and cancer. EMBO J. 2010;29(15):2475-2476.
28. Machida K, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A. 2009;106(5):1548-1553.
29. Chiou SH, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010;70(24):10433- 10444.
30. Jeter CR, et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells. 2009;27(5):993-1005.
31. Yang X, Fraser M, Moll UM, Basak A, Tsang BK. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 2006;66(6):3126-3136.
32. Wei LH, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene. 2001;20(41):5799-5809.
33. Wu HH, et al. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. Clin Cancer Res. 2010;16(21):5200-5210.
34. Arafa el SA, et al. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009;69(23):8910-8917.
35. Tindle RW. Immune evasion in human papillo-mavirus- associated cervical cancer. Nat Rev Cancer. 2002;2(1):59-65. (Pubitemid 37328808)
36. Piersma SJ, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67(1):354-361. (Pubitemid 46142795)
37. Eerola AK, Soini Y, Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcol cinoma. Clin Cancer Res. 2000;6(5):1875-1881. (Pubitemid 30305084)
38. Patel S, Chiplunkar S. Host immune responses to cervical cancer. Curr Opin Obstet Gynecol. 2009;21(1):54-59.
39. Huang CH, et al. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther. 2005;12(15):1180-1186. (Pubitemid 41136312)
40. Noh KH, et al. Activation of Akt as a mechanism for tumor immune evasion. Mol Ther. 2009; 17(3):439-447.
41. Kang TH, Kim KW, Bae HC, Seong SY, Kim TW. Enhancement of DNA vaccine potency by antigen linkage to IFN-gamma-inducible protein-10. Int J Cancer. 2011;128(3):702-714.
42. Kim JH, et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett. 2009;122(1):58-67.
43. Kang TH, et al. Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res. 2010;70(8):3062-3070.
44. Kang TH, et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res. 2007;67(2):802-811.